Urinary tract infections are the most common bacterial infection worldwide, and they don't always get the attention they deserve. 50–60% of women have at least one UTI in their lifetime, women experience UTIs about 30 times more often than men do, and roughly four in ten women who get a UTI will get another within six months.
A long-overdue addition to the toolbox
Most of the antibiotics used for UTI today were developed decades ago. As resistance has grown — particularly in recurrent and complicated cases — the gap between first-line therapy and effective therapy has widened.
GSK's gepotidacin is the first novel oral antibiotic for uncomplicated UTI in roughly twenty years. With a first-in-class mechanism of action, it remains active against strains that have become resistant to existing first-line agents. Phase III data have been strong enough that gepotidacin is widely viewed as a meaningful addition to the UTI armamentarium.
New drugs alone won't solve resistance
Every new antibiotic enters a race against resistance. The faster and more broadly it is used, the faster resistance accumulates. We've watched this pattern repeat for fluoroquinolones, beta-lactams, and most other classes that once seemed durable.
Diagnostics are how that race gets slowed down. When clinicians know up front which pathogen is present and which resistance markers it carries, they can choose the narrowest effective antibiotic — preserving newer agents like gepotidacin for the cases that actually need them.
The diagnostic–therapeutic partnership
The most durable improvements in UTI care come from pairing new therapeutics with precision diagnostics. The BIOTIA-ID Urine Test uses next-generation sequencing to identify 40+ urogenital pathogens and a comprehensive panel of resistance markers from a single urine sample — exactly the kind of upfront information that lets stewardship work in practice, not just on paper.
Frequently asked questions
Why are UTIs so hard to treat?
Roughly 50–60% of women experience at least one UTI in their lifetime, and 4 in 10 will have another within six months. As resistance grows, first-line antibiotics fail more often — particularly in recurrent and complicated cases.
What is gepotidacin?
Gepotidacin is a novel oral antibiotic with a first-in-class mechanism of action, developed by GSK. It targets uncomplicated urinary tract infection and has shown efficacy against strains resistant to existing first-line agents.
Will new antibiotics solve resistance?
Not on their own. New antibiotics buy time, but their useful life is determined by how carefully they are prescribed. Diagnostics that identify pathogens and resistance markers up front are how we make a new drug last more than a few years.